Vitamin D3

With peptides

Vitamin D3 is foundational micronutrient support that pairs with virtually any peptide protocol via immune and bone-health pathways. Healing peptides like BPC-157 and TB-500 for tissue repair benefit from adequate vitamin D status as foundational substrate. GH-secretagogue peptides like sermorelin and CJC-1295 for IGF-1 axis support work alongside vitamin D's bone-supporting effects. Thymosin alpha-1 (Tα1) for immune support has its own mechanism but compatible with vitamin D-mediated immune competence.

With supplements

1. Magnesium — cofactor for vitamin D activation enzymes. Adequate magnesium status is required for normal vitamin D response. The most frequent corrective intervention for non-responders.
2. Calcium — foundational bone-health pairing. Bolland 2018 documented bone benefit emerges with combined D + calcium in deficient elderly specifically. 1000–1200 mg/day from food + supplementation as needed.
3. Vitamin K2 (MK-7 form) — the calcium-routing co-supplementation debate. 90–180 mcg/day at higher chronic vitamin D doses. Mechanistic plausibility; outcome evidence still developing.
4. Fish oil — both fat-soluble; take together with fat-containing meal. Complementary cardiovascular and immune support pairing. VITAL trial tested both — null on hard endpoints individually.
5. Vitamin C — different mechanism but compatible immune support pairing.
6. Zinc — complementary immune support; foundational mineral.
7. Probiotics — gut-immune axis support; vitamin D's VDR signaling in intestinal epithelium complements probiotic microbiome support.
8. Collagen peptides — connective tissue support; compatible bone-and-joint stack.
9. Boron — modest interaction with vitamin D metabolism; some research supports co-supplementation for bone health.

With lifestyle

1. Sun exposure. 10–30 minutes of midday sun on bare arms and legs 2–3 times per week produces meaningful endogenous vitamin D in users with lighter skin in summer at temperate latitudes. Northern latitudes, winter, darker skin pigmentation, and sun avoidance all reduce endogenous production. Sun + dietary + supplemental together optimize status.
2. Test, don't guess. 25-OH-D blood testing is widely available ($30–100 retail or $0 with most insurance for medical indication). Individualization is much more reliable than generic dosing.
3. Dietary sources. Fatty fish (salmon, mackerel, sardines), egg yolks, fortified dairy, fortified plant milks. Modest contribution; supplementation is usually still needed for status optimization.
4. Body fat consideration. Vitamin D distributes into body fat — obese users often need higher supplemental doses to reach the same serum 25-OH-D. Practical implication: 2–3x typical dose may be needed in users with high BMI.
5. Aging and skin synthesis decline. Endogenous skin synthesis declines with age. Older adults benefit more from supplementation than younger users.
6. Pregnancy and breastfeeding. Increased requirements. Obstetric supervision.
7. Avoid high-bolus dosing. Sanders 2010 paradox. Daily or weekly dosing is preferred over monthly or annual.
8. Limit unnecessary expectations. VITAL trial documented null cancer and CV prevention. Don't expect supplementation to do what observational associations suggested.

Common (mostly transient)

1. No common side effects at standard supplemental doses in healthy adults.
2. Mild GI upset at very high doses — uncommon at typical maintenance doses.
3. Sleep disturbance with evening dosing in some users (anecdotal).

Less common (watch-list)

1. Hypercalcemia at toxic doses. Typically 10,000+ IU/day chronically without monitoring. Symptoms: nausea, weakness, frequent urination, kidney problems, hypercalciuria, kidney stones. Reversible with discontinuation.
2. Sarcoidosis and granulomatous diseases. These conditions can produce extra-renal 1,25-D, causing hypercalcemia at lower vitamin D intake than otherwise. Coordinate with treating team.
3. Primary hyperparathyroidism. Altered calcium-vitamin D regulation. Endocrinology supervision.
4. Certain lymphomas. Some lymphomas produce 1,25-D ectopically. Hematology supervision.
5. Williams syndrome. Rare genetic condition with vitamin D hypersensitivity.
6. Kidney disease. Impaired 1,25-D synthesis; specialized vitamin D analogs (calcitriol, paricalcitol) often used instead of standard D3. Nephrology coordination.
7. Fall risk at high-bolus doses. Sanders 2010 paradox in older women. Avoid high-bolus dosing for fall prevention.

Drug and supplement interactions

1. Thiazide diuretics. Reduce urinary calcium excretion; vitamin D + thiazide may cause hypercalcemia. Monitor.
2. Digoxin. Vitamin D-induced hypercalcemia increases digoxin toxicity risk. Monitor.
3. Corticosteroids. Reduce calcium absorption; vitamin D supplementation often needed for users on chronic corticosteroids.
4. Anticonvulsants (phenytoin, phenobarbital). Induce vitamin D catabolism; users may need higher doses.
5. Statins. Modest interaction; clinical significance small.
6. Cholestyramine and bile acid sequestrants. Reduce fat-soluble vitamin absorption; separate timing.
7. Orlistat (weight loss medication). Reduces fat absorption including vitamin D. Compensate with higher dose.
8. Pregnancy — supplementation is recommended at moderate doses; coordinate dose with obstetrician.

How much vitamin D3 should I take?

Depends on baseline status. The honest answer requires individualization based on 25-OH-D blood testing. General maintenance for users with adequate sun exposure and Mediterranean-style diet: 1000–2000 IU/day (matches Endocrine Society recommendations). For documented deficiency (25-OH-D below 20 ng/mL): 4000–10,000 IU/day for 6–12 weeks to correct, then maintenance dose. Higher doses (above 4000 IU/day chronically) should be under healthcare provider guidance with periodic 25-OH-D monitoring. NAS tolerable upper intake level is 4000 IU/day; Endocrine Society allows up to 10,000 IU/day in healthy adults. Practical approach: test 25-OH-D first; choose dose based on baseline; retest at 3 months and adjust. Target range: 30–50 ng/mL per most guidelines (some advocates target higher, but evidence for benefit above 50 ng/mL is weaker than below).

Why D3 (cholecalciferol) instead of D2 (ergocalciferol)?

D3 raises serum 25-OH-D levels more efficiently. Head-to-head trials document D3 is approximately 87% more effective than D2 at raising 25-OH-D per equivalent dose. The mechanism: D3 binds vitamin D binding protein with higher affinity and has a longer half-life in circulation. Practical implication: always choose D3 (cholecalciferol) over D2 (ergocalciferol) for supplementation. D2 is the prescription form sometimes used in clinical contexts (massive bolus 50,000 IU doses), but for daily supplementation D3 is unambiguously preferred. D3 is available from animal sources (lanolin from sheep wool) or lichen-derived for vegan supplementation. Both raise 25-OH-D equivalently when at matched dose.

Does vitamin D actually prevent falls in older adults?

This is more contested than the older guidance suggested. Older Bischoff-Ferrari meta-analyses supported fall reduction with moderate-dose vitamin D in older adults. But two important developments complicated the picture: (1) USPSTF 2018 recommended AGAINST routine vitamin D supplementation for fall prevention in community-dwelling older adults — concluding evidence was insufficient or did not support net benefit. (2) Sanders 2010 JAMA — an annual high-dose (500,000 IU) vitamin D trial in older women — paradoxically INCREASED falls and fractures. The mechanism for the paradox isn't fully resolved (possibly behavioral — users feeling stronger and being less cautious; possibly metabolic). The current honest framing: vitamin D may modestly reduce falls in deficient elderly populations at moderate doses (800–1000 IU/day); high-bolus dosing (e.g., 50,000+ IU annual or monthly) has paradoxical evidence and is not recommended for fall prevention. Bone health benefits (with calcium) remain the cleanest Strong evidence endpoint; fall reduction is Moderate/contested.

Will vitamin D supplementation reduce my cancer or heart disease risk?

Probably not, based on the strongest RCT evidence. The VITAL trial (Manson 2019 NEJM) randomized over 25,000 adults to 2000 IU/day vitamin D3 vs placebo over ~5 years and found NO significant reduction in cancer incidence, cardiovascular events, or total mortality. The trial was specifically designed to test the cancer and CV prevention hypotheses suggested by observational studies. Smaller follow-up analyses have suggested benefit in specific subgroups (cancer mortality, advanced cancer) but the primary endpoints were null. Honest framing: observational associations between low vitamin D and higher cancer/CV risk likely reflect deficiency as a marker of broader health rather than supplementation as a treatment. Supplementation in already-replete individuals does NOT reduce cancer or CV risk. For deficient users, correcting deficiency may have benefit, but expecting routine supplementation to prevent these diseases isn't supported by VITAL-level evidence.

Do I need to take K2 with my vitamin D?

Debated, with reasonable arguments but limited definitive evidence. The K2 co-supplementation argument: vitamin D drives calcium absorption from gut; vitamin K2 activates osteocalcin (which directs calcium to bone) and matrix Gla-protein (which prevents calcium deposition in arteries). Without adequate K2, the calcium that D drives absorption of theoretically routes to arteries rather than bone. The argument has biological plausibility. The evidence base: K2 (specifically the MK-7 form) has documented effects on bone density and arterial calcification markers in osteoporosis and CV risk populations. Whether routine K2 co-supplementation with vitamin D produces meaningful clinical outcome improvements vs vitamin D alone isn't definitively established in large outcome trials. Practical guidance: at standard maintenance doses (1000–2000 IU vitamin D/day), K2 co-supplementation is reasonable but not strictly necessary. At higher vitamin D doses (4000+ IU/day chronically), K2 (90–180 mcg MK-7 form) may be more relevant. Eat fermented foods (natto, sauerkraut) and leafy greens for K2 and K1 dietary sources.

Will vitamin D help me avoid catching the flu or COVID?

Modestly for respiratory infections in deficient users — and the effect is smaller than early enthusiasm suggested. Martineau 2017 BMJ meta-analysis of 25 RCTs (11,321 participants) documented vitamin D supplementation modestly reduced acute respiratory tract infection risk, with largest benefit in users deficient at baseline (25-OH-D below 25 nmol/L = 10 ng/mL). For users with adequate baseline status, supplementation effect was small. COVID-19 observational studies during the pandemic consistently associated low vitamin D status with worse outcomes; RCTs of supplementation for COVID-19 prevention or treatment have been more mixed. Honest framing: maintaining sufficient vitamin D status (avoiding deficiency) supports respiratory immune function modestly; high-dose supplementation in already-replete users isn't reliable URTI/COVID prevention. Routine flu shots and other established interventions matter more than vitamin D for infection prevention.

What's the difference between 25-OH-D and 1,25-D?

Different forms in the vitamin D activation cascade. 25-hydroxyvitamin D (25-OH-D, calcidiol) is the storage form in circulation — what blood tests measure and what reflects your vitamin D status. 1,25-dihydroxyvitamin D (1,25-D, calcitriol) is the hormonally active form, produced in the kidneys (and locally in many tissues) under tight regulation by parathyroid hormone, calcium, and phosphate. 1,25-D is what binds vitamin D receptors and exerts effects. Practically: when discussing vitamin D "levels" or supplementation, we mean 25-OH-D. Target ranges: below 20 ng/mL = deficient; 20–29 = insufficient; 30–50 = sufficient (most guidelines); 50–80 = optimal per some advocates; above 100 = excessive. The 1,25-D form is rarely measured routinely except in specific clinical contexts (kidney disease, sarcoidosis, primary hyperparathyroidism).

Why does magnesium matter for vitamin D activation?

Magnesium is the cofactor for both the activation cascade and the binding step. Magnesium is required for the enzymes that convert vitamin D3 to 25-OH-D (in liver) and 25-OH-D to active 1,25-D (in kidney). Magnesium is also required for vitamin D binding protein function. Severe magnesium deficiency can impair vitamin D activation — explaining why some users don't respond to vitamin D supplementation as expected. Practical implication: ensure adequate magnesium status (200–400 mg/day from food + supplementation as needed) when taking vitamin D, particularly at higher doses. Magnesium deficiency is common (~50% of US adults below RDA) and is the more-frequent corrective intervention for non-responders to vitamin D supplementation.